Allogeneic HCT Rebounds, PTCy Reshapes Donor Choice, and CAR‑T Use Surges: Key Trends from the 2013–2023 CIBMTR Activity Report
Posted inHematology-Oncology news

Allogeneic HCT Rebounds, PTCy Reshapes Donor Choice, and CAR‑T Use Surges: Key Trends from the 2013–2023 CIBMTR Activity Report

CIBMTR's 2013–2023 registry update shows a 2023 rebound in allogeneic HCT—driven by older adults—widespread adoption of post‑transplant cyclophosphamide (PTCy) across donor types, increasing mismatched donor use, and rapid expansion of commercial CAR‑T therapy; relapse remains the leading cause of death.
Donor CMV Seropositivity Tied to Worse Survival in CMV‑Seronegative AML Patients Undergoing Unrelated HCT with Post‑Transplant Cyclophosphamide
Posted inHematology-Oncology news

Donor CMV Seropositivity Tied to Worse Survival in CMV‑Seronegative AML Patients Undergoing Unrelated HCT with Post‑Transplant Cyclophosphamide

In CMV‑seronegative adult AML recipients receiving unrelated donor hematopoietic cell transplantation with PTCy, donor CMV seropositivity was associated with worse overall survival—primarily through a trend toward higher relapse—supporting consideration of donor CMV serostatus in selection.
Prolonged Hospitalization Post-Hematopoietic Cell Transplantation: Identifying Risk Factors and Impacts on Patient Outcomes
Posted inClinical Updates Hematology-Oncology Specialties Transplantation

Prolonged Hospitalization Post-Hematopoietic Cell Transplantation: Identifying Risk Factors and Impacts on Patient Outcomes

This study reveals that prolonged hospitalization after hematopoietic cell transplantation correlates with worse quality of life, greater symptom burden, increased depressive symptoms, and higher risk of rehospitalization and mortality within one year post-transplant.